M. Loubidiab,
C. Pillardc,
A. El Hakmaouib,
P. Bernardc,
M. Akssira*b and
G. Guillaumet*a
aInstitut de Chimie Organique et Analytique, Université d’Orléans, UMR CNRS 7311, 45067 Orléans Cedex, France. E-mail: gerald.guillaumet@univ-orleans.fr
bEquipe de Chimie Bioorganique & Analytique, URAC 22 Université Hassan II Mohammedia-Casablanca, BP 146, 28800 Mohammedia, Morocco
cGreenpharma S.A.S., 3, allée du Titane, 45100, Orleans, France
First published on 8th January 2016
We report herein a synthetic pathway to new 7-bromo-1-(4-methoxybenzyl)-5-methyl-imidazo[1,5-a]imidazole-2-one. The synthetic potential of this scaffold was demonstrated by displacing bromine by Suzuki–Miyaura cross-coupling reactions. A large panel of boronic acids (aryl, heteroaryl or vinyl) were easily introduced, giving access to a broad and diversified library of 1-(4-methoxybenzyl)-5-methyl-7-(substituted)-imidazo[1,5-a]imidazole-2-ones.
Among nitrogen cycles, 5–5 bicycles have received particular attention due to their biologically interesting properties exploited in drug manufacture.2 The imidazo[1,5-a]imidazole is a nitrogenous heterocycle with significant interest in drug synthesis and functionalization. It was reported that its oxoanalog imidazo[1,5-a]imidazolinone has also proved to be a structurally pertinent skeleton for the development of biologically active and pharmaceutically relevant compounds.3
Current strategies for preparing imidazo[1,5-a]imidazolinone derivatives generally consist in building the 5–5 fused ring with the desired substituents in appropriate position.4 A careful literature survey revealed that no method for the functionalization of the heterocyclic moiety has yet been described. In this context, the overall goal of our research was to develop an efficient synthesis of imidazo[1,5-a]imidazole-2-one synthon that permits its subsequent functionalization, thereby enabling molecular diversity.
Based on the interest of our group in the synthesis of nitrogen-based heterocycles,5 we disclose herein the access to a library of original 5-methyl-7-(hetero)arylated-imidazo[1,5-a]imidazole-2-one derivatives. Our synthetic strategy is based on an efficient four-step synthesis of the bicycle followed by palladium catalyzed Suzuki–Miyaura cross-coupling.6 To the best of our knowledge, no example of palladium cross-coupling reaction on the imidazo[1,5-a]imidazolinone core has yet been reported.
The condensation reaction between 2 and 4 was performed in the presence of sodium hydride in dry tetrahydrofuran and afforded amide 5 in 90% yield (Scheme 1).9
Product 5 was engaged in an intramolecular cyclization. First, a Buchwald-type cyclization using palladium acetate, xantphos as ligand and cesium carbonate as base was tested10 (Table 1, entries 1–4) but low conversion was observed. Replacing the catalyst by copper iodide11 resulted in better conversion (Table 1, entry 5). The use of K3PO4 as base considerably improved the conversion rate to 89% in toluene and to 80% in N,N-dimethylformamide (Table 1, entries 6 and 7). The addition of a ligand such as N,N′-dimethylethylenediamine12 did not improved the yield (Table 1, entries 8 and 9). We also carried out the reaction in different solvents (Table 1, entries 10–12). Finally, a total conversion was obtained in toluene at 160 °C during 4 hours (Table 1, entry 13). We also found that the heating system has a significant influence, since heating in a sealed tube for 20 hours also led to a conversion rate of 100%, and a yield after column chromatography of 81% (Table 1, entry 15). To complete the optimization, we evaluated the impact of the amount of base and CuI. Decreasing the quantity of K3PO4 to 2 equivalents did not maintain a coupling efficiency (Table 1, entry 16). On the other hand, the catalyst loading could be reduced to 10 mol% of CuI without impacting the yield of the reaction (Table 1, entry 17). However 5 mol% involved a partial conversion rate and a low yield (Table 1, entry 18).
Entry | Catalyst | Ligand | Base | Solvent | Time (h) | T (°C) | Heating system | Conv.a | Yieldb |
---|---|---|---|---|---|---|---|---|---|
a 1H NMR ratio based on the integration of CH3.b Yield of isolated product after column chromatography.c Degradation of the reaction mixture.d With 10 mol% of copper iodide (CuI).e With 5 mol% of copper iodide (CuI).f 100% of starting material 5 is recovered. | |||||||||
1 | Pd(OAc)2 | Xantphos | Cs2CO3 (2 eq.) | 1,4-Dioxane | 4 | 150 °C | MW | 0 | —c |
2 | Pd(OAc)2 | Xantphos | Cs2CO3 (2 eq.) | t-BuOH | 4 | 150 °C | MW | 0 | —c |
3 | Pd(OAc)2 | Xantphos | Cs2CO3 (2 eq.) | Toluene | 4 | 150 °C | MW | 38 | 29 |
4 | Pd(OAc)2 | Xantphos | Cs2CO3 (4 eq.) | Toluene | 4 | 150 °C | MW | 46 | 37 |
5 | CuI | — | Cs2CO3 (4 eq.) | Toluene | 4 | 150 °C | MW | 72 | 55 |
6 | CuI | — | K3PO4 (4 eq.) | Toluene | 4 | 150 °C | MW | 89 | 74 |
7 | CuI | — | K3PO4 (4 eq.) | DMF | 4 | 150 °C | MW | 80 | 58 |
8 | CuI | DMEDA | K3PO4 (4 eq.) | DMF | 2 | 150 °C | MW | 55 | 42 |
9 | CuI | DMEDA | Cs2CO3 (4 eq.) | DMF | 2 | 150 °C | MW | 28 | 19 |
10 | CuI | — | K3PO4 (4 eq.) | 1,4-Dioxane | 4 | 150 °C | MW | 0 | —c |
11 | CuI | — | K3PO4 (4 eq.) | Toluene/DMF (4/1) | 4 | 150 °C | MW | 57 | 44 |
12 | CuI | — | K3PO4 (4 eq.) | Toluene/ethanol (4/1) | 4 | 150 °C | MW | 25 | 17 |
13 | CuI | — | K3PO4 (4 eq.) | Toluene | 4 | 160 °C | MW | 100 | 80 |
14 | CuI | — | K3PO4 (4 eq.) | Toluene | 16 | 150 °C | Sealed tube | 87 | 68 |
15 | CuI | — | K3PO4 (4 eq.) | Toluene | 20 | 150 °C | Sealed tube | 100 | 81 |
16 | CuI | — | K3PO4 (2 eq.) | Toluene | 20 | 150 °C | Sealed tube | 57 | 46 |
17 | CuId | — | K3PO4 (4 eq.) | Toluene | 20 | 150°C | Sealed tube | 100 | 80 |
18 | CuIe | — | K3PO4 (4 eq.) | Toluene | 20 | 150 °C | Sealed tube | 78 | 64 |
19 | — | — | K3PO4 (4 eq.) | Toluene | 4 | 160 °C | MW | 0 | —f |
These functionalizable intermediate 6 open the way to design a chemical library of imidazo[1,5-a]imidazolinone derivatives from the bromide in position 7.
Initial optimization trials of the Suzuki–Miyaura cross coupling reaction were performed on the imidazole skeleton 6 synthesized previously using p-tolylboronic acid. As a model, we began with the investigation using different palladium sources, (palladium(II) acetate, [1,1 bis(diphenylphosphino) ferrocene]dichloropalladium) complexed with dichloromethane Pd(dppf)Cl2·CH2Cl2, or bis(dibenzylideneacetone)palladium(0) as the catalyst, potassium carbonate as the base and a mixture of 1,4-dioxane/ethanol 2/1 as solvent. The coupling product 7 was obtained in the three tests with acceptable yields but with only a partial conversion rate (Table 2, entries 1–3).
Entry | Catalyst | Ligand | Solvent | Time [min] | Heating system | Conv.a [%] | Yieldb [%] |
---|---|---|---|---|---|---|---|
a 1H NMR ratio based on the integration of CH3 or OCH3.b Yield of isolated product after column chromatography. | |||||||
1 | Pd(OAc)2 | Xantphos | 1,4-Dioxane/EtOH (2/1) | 180 | Reflux | 82 | 61 |
2 | Pd(dppf)Cl2·CH2Cl2 | — | 1,4-Dioxane/EtOH (2/1) | 90 | Reflux | 91 | 72 |
3 | Pd2(dba)3 | — | 1,4-Dioxane/EtOH (2/1) | 90 | Reflux | 71 | 44 |
4 | Pd(dppf)Cl2·CH2Cl2 | — | 1,4-Dioxane | 90 | Reflux | 52 | 21 |
5 | Pd(OAc)2 | Xantphos | Toluene/EtOH (2/1) | 180 | Reflux | 90 | 67 |
6 | Pd(dppf)Cl2·CH2Cl2 | — | Toluene/EtOH (2/1) | 90 | Reflux | 100 | 88 |
7 | Pd2(dba)3 | — | Toluene/EtOH (2/1) | 90 | Reflux | 79 | 51 |
8 | Pd(dppf)Cl2·CH2Cl2 | — | Toluene/EtOH (2/1) | 20 | MW, 130 °C | 100 | 73 |
Without ethanol, even after 90 minutes of heating, only 52% of conversion was achieved (Table 2, entry 4), showing that a protic solvent is essential in this coupling process.
Replacing 1,4-dioxane by toluene led to a significant increase in conversion rate (Table 2, entries 5–7). The best conditions were found with a mixture of toluene/ethanol 2/1 as solvent. We next focused our attention on the influence of the catalyst. The use of palladium(0) instead a palladium(II) (i.e. Pd2dba3 in replacement of Pd(OAc)2 or Pd(dppf)Cl2·CH2Cl2), the yield significantly decreased (Table 2, entries 5–7). Finally, replacing conventional thermal heating by microwave irradiation produced no real improvement in terms of yield and time (Table 2, entry 8).
Optimum conditions were found to be boronic acid (1.5 equiv.), Pd(dppf)Cl2·CH2Cl2 (0.10 equiv.), K2CO3 (1.5 equiv.) in a mixture of toluene/ethanol 2/1, refluxing for a short time of 1.5 hour.
To explore the scope of the methodology, we applied these selected conditions using different boronic acids. Gratifyingly, the optimized conditions proved to be efficient with boronic acids containing a large variety of functional groups. More precisely, para-substituted phenylboronic acids bearing electron-rich (CH3, OCH3) or electron-poor (COOEt, NO2, CF3, CN) groups led to 7-aryl-1H-imidazo[1,5-a]imidazole-2-ones in good yields (Table 3, entries 1–7). Notably, meta-substitution did not disfavor the cross-coupling reaction. In fact, derivatives 15–18 were obtained in satisfactory yields (Table 3, entries 9–12). However, using ortho-substituted phenylboronic acids provided only the dehalogenation product 19 (Table 3, entries 13–15). Steric hindrance could explain this result.
Finally, heterocycles such as 3-furane and 3-thiophene were introduced with moderate yields of 46% and 65% respectively (Table 3, entries 17 and 18). The strategy was also compatible with vinylboronic acid, since styryl derivative 20 was obtained in 67% yield (entry 16).
White solid (9.06 g, 62%); mp 235–237 °C (ref. 13, 239–240 °C), IR (neat, cm−1): 1397, 1556, 3122, 3216, 3490; 1H NMR (400 MHz, DMSO-d6): δ 2.23 (s, 3H, CH3); 13C NMR (101 MHz, DMSO-d6): δ 14.3, 105.95 (2C), 146.0 (CIV); HRMS (ESI): calcd for C4H5Br2N2 238.88140 [M + H]+, 260.86334 [M + Na]+ found 238.88134 [M + H]+ 260.86327 [M + Na]+.
White solid (8.9 g, 95%); mp: 119–121 °C (ref. 14, 120–121 °C); IR (neat, cm−1): 818, 1030, 1179, 1212, 1243, 1512, 1645, 3280; 1H NMR (400 MHz, CDCl3): δ 3.81 (s, 3H), 3.92 (s, 2H), 4.41 (d, J = 5.7 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 6.70 (br. s, 1H), 7.22 (d, J = 8.5 Hz, 2H); 13C NMR (101 MHz, DMSO-d6): δ 29.5, 42.0, 55.1, 113.8 (2C), 128.7 (2C), 130.1, 158.3, 165.9; HRMS (ESI): calcd for C10H13BrNO2 258.01242 [M + H]+ 279.99436 [M + Na]+ found 258.01227 [M + H]+ 279.9944 [M + Na]+.
White solid (9.90 g, 90%); mp: 132–134 °C; IR (neat, cm−1): 700, 846, 1017, 1245, 1462, 1504, 1600; 1H NMR (250 MHz, DMSO-d6): δ 2.28 (s, 3H), 3.73 (s, 3H), 4.25 (d, J = 5.7 Hz, 2H), 4.69 (s, 2H), 6.90 (d, J = 8.7 Hz, 2H), 7.20 (d, J = 8.7 Hz, 2H), 8.73 (s, 1H); 13C NMR (101 MHz, DMSO-d6): δ 13.8, 42.1, 48.1, 55.3, 103.3 (2C), 114.0 (2C), 128.8 (2C), 130.8, 147.3, 158.5, 165.6; HRMS (ESI): calcd for C14H16Br2N3O2 415.9606 [M + H]+ found 415.9604 [M + 1]+.
White solid (328 mg, 81%); mp: 132–134 °C; IR (neat, cm−1): 810, 1239, 1577, 1730, 2940; 1H NMR (400 MHz, CDCl3): δ 2.28 (s, 3H), 3.77 (s, 3H), 4.35 (s, 2H), 4.86 (s, 2H), 6.84 (d, J = 8.3 Hz, 2H), 7.39 (d, J = 8.3 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.4, 43.7, 47.7, 55.4, 86.9, 114.2 (2C), 127.7, 129.9 (2C), 132.6, 138.3, 159.6, 169.8; HRMS (ESI): calcd for C14H15BrN3O2 336.03394 [M + H]+ found 336.03421 [M + H]+.
Brown solid (88 mg; 85%); mp: 152–153 °C; IR (neat, cm−1): 825, 1247, 1514, 1608, 1720, 2919; 1H NMR (400 MHz, CDCl3): δ 2.34 (s, 3H), 2.37 (s, 3H), 3.72 (s, 3H), 4.41 (s, 2H), 4.82 (s, 2H), 6.67 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 7.9 Hz, 2H), 7.27 (d, J = 7.9 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.0, 21.0, 44.1, 46.9, 55.3, 114.0 (2C), 118.0, 127.7, 128.6 (2C), 128.6 (2C), 129.9 (2C), 130.7, 131.4, 136.8, 137.7, 159.3, 170.9; HRMS (ESI): calcd for C21H22N3O2 348.17084 [M + H]+ found 348.17065 [M + H]+.
Brown solid (85 mg; 79%); mp: 175–177 °C; IR (neat, cm−1): 811, 1029, 1184, 1230, 1525, 1572, 1730; 1H NMR (400 MHz, CDCl3): δ 2.33 (s, 3H), 3.71 (s, 3H), 3.82 (s, 3H), 4.41 (s, 2H), 4.79 (s, 2H), 6.67 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.0, 47.2, 55.3, 113.9 (2C), 114,0 (2C), 117.5, 126.2, 127.7, 129.2 (2C), 130.0 (2C), 131.1, 137.6, 158.9, 159.2, 170.8; HRMS (ESI): calcd for C21H22N3O3 364.16557 [M + H]+ found 364.16579 [M + H]+.
White solid (93 mg; 79%); mp: 110–112 °C; IR (neat, cm−1): 842, 1061, 1177, 1247, 1513, 1597, 1722; 1H NMR (400 MHz, CDCl3): δ 2.34 (s, 3H), 3.71 (s, 9H), 4.41 (s, 2H), 4.87 (s, 2H), 6.40 (s, 1H), 6.55 (s, 2H), 6.68 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.2, 47.2, 55.3 (3C), 100.0, 106.7 (2C), 114.0 (2C), 118.0, 127.6, 129.1 (2C), 131.6, 135.6, 137.7, 159.8, 160.8 (2C), 170.9; HRMS (ESI): calcd for C22H24N3O4 394.17596 [M + H]+ found 394.17613 [M + H]+.
Brown solid (100 mg; 83%); mp: 173–175 °C; IR (neat, cm−1): 990, 1175, 1248, 1510, 1607, 1722, 2835; 1H NMR (400 MHz, CDCl3): δ 1.43 (t, J = 7.1 Hz, 3H), 2.40 (s, 3H), 3.75 (s, 3H), 4.43 (q, J = 7.1 Hz, 2H), 4.49 (s, 2H), 4.90 (s, 2H), 6.72 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 8.03 (d, J = 8.1 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.4, 14.5, 44.4, 47.2, 55.4, 61.1, 114.2 (2C), 117.4, 127.2, 128.1 (2C), 128.9, 129.8 (2C), 130.0 (2C), 132.7, 138.2, 138.5, 159.4, 166.7, 171.1; HRMS (ESI): calcd for C23H24N3O4 406.17607 [M + H]+ found 406.17613 [M + H]+.
Brown solid (92 mg; 82%); mp: 169–171 °C; IR (neat, cm−1): 814, 1048, 1097, 1249, 1318, 1509, 1723, 2923; 1H NMR (400 MHz, CDCl3): δ 2.39 (s, 3H), 3.74 (s, 3H), 4.52 (s, 2H), 4.91 (s, 2H), 6.74 (d, J = 8.0 Hz, 2H), 6.91 (d, J = 7.9 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), δ 8.15 (d, J = 7.9 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.6, 47.2, 55.4, 114.4 (2C), 116.4, 123.9 (2C), 126.7, 128.3 (2C), 128.4 (2C), 133.6, 139.1, 140.4, 146.3, 159.5, 171.1; HRMS (ESI): calcd for C20H19N4O4 379.14009 [M + H]+ found 379.14008 [M + H]+.
White solid (96 mg; 80%); mp: 195–197 °C; IR (neat, cm−1): 858, 1062, 1102, 1245, 1317, 1600, 1721, 2930; 1H NMR (400 MHz, CDCl3): δ 2.37 (s, 3H), 3.73 (s, 3H), 4.48 (s, 2H), 4.86 (s, 2H), 6.69 (d, J = 8.3 Hz, 2H), 6.84 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.56 (d, J = 8.0 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.4, 47.2, 55.4, 114.2 (2C), 116.9, 124.4 (q, 1JC–F = 273 Hz, CF3), 125.36 (2C) (q, 3JCHAr–F = 3.8 Hz, CHAr), 127.0, 128.5 (2C), 128.6 (2C), 128.9 (q, 2JCIV–F = 32.4 Hz, CIV), 132.6, 137.3, 138.5, 159.4, 171.0; HRMS (ESI): calcd for C21H19F3N3O2 402.14217 [M + H]+ found 402.14239 [M + H]+.
Brown solid (65 mg; 61%); mp: 137–139 °C; IR (neat, cm−1): 844, 1296, 1509, 1605, 1720, 2215; 1H NMR (400 MHz, CDCl3): δ 2.38 (s, 3H), 3.75 (s, 3H), 4.51 (s, 2H), 4.88 (s, 2H), 6.73 (d, J = 8.1 Hz, 2H), 6.88 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 7.7 Hz, 2H), 7.58 (d, J = 7.7 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.4, 44.5, 47.2, 55.4, 110.0, 114.3 (2C), 116.7, 119.2, 126.8, 128.5 (2C), 128.4 (2C), 132.2 (2C), 133.0, 138.4, 138.8, 159.5, 171.1; HRMS (ESI): calcd for C21H18N4O2 359.15007 [M + H]+ found 359.15025 [M + H]+.
Brown solid (74 mg; 75%); mp: 126–128 °C; IR (neat, cm−1): 769, 1031, 1252, 1332, 1615, 1700; 1H NMR (400 MHz, CDCl3): δ 2.35 (s, 3H), 3.71 (s, 3H), 4.42 (s, 2H), 4.83 (s, 2H), 6.66 (d, J = 8.8 Hz, 2H), 6.8 (d, J = 8.8 Hz, 2H), 7.25–7.32 (m, 1H), 7.36 (q, J = 7.7 Hz, 4H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.1, 47.2, 55.3, 114.0 (2C), 118.0, 127.1, 127.6 (2C), 128.4 (2C), 128.7 (2C), 129.2, 131.6, 133.7, 137.8, 159.2, 170.9; HRMS (ESI): calcd for C20H20N3O2 334.15488 [M + H]+; found 334.15500 [M + H]+.
Brown solid (82 mg; 79%); mp: 142–143 °C; IR (neat, cm−1): 825, 1246, 1513, 1637, 1721, 2920; 1H NMR (400 MHz, CDCl3): δ 2.32 (s, 3H), 2.35 (s, 3H), 3.72 (s, 3H), 4.43 (s, 2H), 4.84 (s, 2H), 6.68 (d, J = 8.0 Hz, 2H), 6.54 (d, J = 8.0 Hz, 2H), 7.16 (d, J = 7.4 Hz, 1H), 7.20 (d, J = 7.6 Hz, 1H), 7.20 (s, 1H), 7.21–7.25 (m, 1H); 13C NMR (101 MHz, CDCl3): δ 13.3, 21.5, 44.2, 47.20, 55.3, 114.01 (2C), 118.1, 125.8, 127.6, 127.9, 128.27, 129.0 (2C), 129.3, 131.5, 133.5, 137.8, 138.07, 159.3, 170.9; HRMS (ESI): calcd for C21H22N3O2 348.17050 [M + H]+ found 348.17065 [M + H]+.
White solid (88 mg; 74%); mp: 156–158 °C; IR (neat, cm−1): 804, 1034, 1103, 1175, 1266, 1305, 1512, 1729, 2928; 1H NMR (400 MHz, CDCl3): δ 2.38 (s, 3H), 3.74 (s, 3H), 4.51 (s, 2H), 4.83 (s, 2H), 6.65 (d, J = 8.5 Hz, 2H), 6.77 (d, J = 8.5 Hz, 2H), 7.41 (d, J = 7.7 Hz, 1H), 7.51–7.44 (m, 2H), 7.63 (s, 1H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.2, 47.2, 55.3, 113.8 (2C), 116.5, 123.4 (q, JC–F = 3.7 Hz), 123.9 (q, JC–F = 273 Hz, CF3), 125.0 (q, JC–F = 3.7 Hz), 126.6, 128.3 (2C), 128.5, 130.5 (q, J = 32.2 Hz), 131.5, 132.3, 134.6, 138.3, 159.4, 170.9; HRMS (ESI): calcd for C21H19F3N3O2 402.14226 [M + H]+ found 402.14239 [M + H]+.
Brown solid (60 mg; 56%); mp: 147–149 °C; IR (neat, cm−1): 805, 1242, 1512, 1605, 1726, 2224; 1H NMR (400 MHz, CDCl3): δ 2.38 (s, 3H), 3.74 (s, 3H), 4.51 (s, 2H), 4.85 (s, 2H), 6.73 (d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 7.40 (t, J = 7.6, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.58 (s, 1H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.4, 47.2, 55.4, 112.6, 114.37 (2C), 116.0, 118.8, 126.7, 128.4 (2C), 129.2, 130.4, 131.6, 132.5, 132.6, 135.0, 138.6, 159.3, 170.8; HRMS (ESI): calcd for C21H19N4O2 359.15012 [M + H]+ found 359.15025 [M + H]+.
White solid; (yield see Table 3 above). mp: 98–100 °C; IR (neat, cm−1): 845, 1027, 1176, 1243, 1512, 1609, 1719, 2927; 1H NMR (400 MHz, CDCl3): δ 2.32 (s, 3H), 3.81 (s, 3H), 4.41 (s, 2H), 4.75 (s, 2H), 6.06 (s, 1H), 6.86 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.3 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.6, 45.2, 47.6, 55.4, 103.2, 114.4 (2C), 126.6, 130.0 (2C), 136.5, 138.1, 160.0, 170.0; HRMS (ESI): calcd for C14H16N3O2 258.12369 [M + H]+ found 258.12370 [M + H]+.
Brown solid (72 mg; 67%); mp: 192–194 °C; IR (neat, cm−1): 918, 1176, 1246, 1511, 1614, 1729; 1H NMR (400 MHz, CDCl3): δ 2.37 (s, 3H), 3.78 (s, 3H), 4.43 (s, 2H), 4.98 (s, 2H), 6.65 (d, J = 15.8 Hz, 1H), 6.92 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 15.8 Hz, 1H), 7.18–7.27 (m, 1H), 7.28–7.32 (m, 6H); 13C NMR (101 MHz, CDCl3): δ 13.4, 44.3, 47.3, 55.4, 114.5 (2C), 116.3, 117.5, 125.2, 126.0 (2C), 126.8, 127.2, 128.5 (2C), 128.6 (2C), 133.0, 138.0, 138.8, 159.6, 170.5; HRMS (ESI): calcd for C22H22N3O2 360.17047 [M + H]+ found 360.17065 [M + H]+.
Brown solid (44 mg; 46%); mp: 167–169 °C; IR (neat, cm−1); 1021, 1176, 1246, 1513, 1581, 1724; 1H NMR (400 MHz, CDCl3): δ 2.34 (s, 3H), 3.75 (s, 3H), 4.43 (s, 2H), 4.84 (s, 2H), 6.47 (s, 1H), 6.77 (d, J = 7.8 Hz, 2H), 7.01 (d, J = 7.8 Hz, 2H), 7.40 (d, J = 5.0 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.0, 47.3, 55.4, 108.8, 111.3, 114.2 (2C), 118.3, 127.4, 128.8 (2C), 132.0, 138.1, 140.0, 143.2, 159.4, 170.4; HRMS (ESI): calcd for C18H18N3O3 324.13425 [M + H]+ found 324.13426 [M + H]+.
White solid (70 mg; 65%); mp: 161–163 °C; IR (neat, cm−1): 863, 1031, 1175, 1248, 1513, 1632, 1723; 1H NMR (400 MHz, CDCl3): δ 2.33 (s, 3H), 3.72 (s, 3H), 4.42 (s, 2H), 4.83 (s, 2H), 6.71 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 3.7 Hz, 2H), 7.33–7.29 (m, 1H); 13C NMR (101 MHz, CDCl3): δ 13.3, 44.0, 47.2, 55.3, 113.1, 114.1 (2C), 122.2, 125.7, 127.6, 128.5, 129.0 (2C), 131.7, 134.2, 137.6, 159.3, 170.6; HRMS (ESI): calcd for C18H18N3O2S 340.11139 [M + H]+ found 340.11142 [M + H]+.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ra25520a |
This journal is © The Royal Society of Chemistry 2016 |